These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 26709984)

  • 21. Predictive value of admission platelet volume indices for in-hospital major adverse cardiovascular events in acute ST-segment elevation myocardial infarction.
    Celik T; Kaya MG; Akpek M; Gunebakmaz O; Balta S; Sarli B; Duran M; Demirkol S; Uysal OK; Oguzhan A; Gibson CM
    Angiology; 2015 Feb; 66(2):155-62. PubMed ID: 24301422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between circulating miRNA-30e and no-reflow phenomenon in STEMI patients undergoing primary coronary intervention.
    Su Q; Ye Z; Sun Y; Yang H; Li L
    Scand J Clin Lab Invest; 2018 Jul; 78(4):318-324. PubMed ID: 29703083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mild to Moderate Renal Impairment Is Associated With No-Reflow Phenomenon After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction.
    Kurtul A; Murat SN; Yarlioglues M; Duran M; Celik IE; Kilic A
    Angiology; 2015 Aug; 66(7):644-51. PubMed ID: 25124682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Importance of Magnesium Values in Patients With STEMI Admitted to the Emergency Department.
    Yuksel M; Isik T; Tanboga IH; Ayhan E; Erimsah ME; Topcu S; Demirelli S; Aksakal E; Sevimli S
    Clin Appl Thromb Hemost; 2017 May; 23(4):329-335. PubMed ID: 27418637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relation of neutrophil/lymphocyte ratio to coronary flow to in-hospital major adverse cardiac events in patients with ST-elevated myocardial infarction undergoing primary coronary intervention.
    Akpek M; Kaya MG; Lam YY; Sahin O; Elcik D; Celik T; Ergin A; Gibson CM
    Am J Cardiol; 2012 Sep; 110(5):621-7. PubMed ID: 22608360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Relation of admission neutrophil/lymphocyte ratio to angiographic no-reflow phenomenon in patients with ST-elevated myocardial infarction undergoing primary coronary intervention].
    Niu X; Zhang Y; He S; Chen D; Yan D; Yao Y
    Zhonghua Liu Xing Bing Xue Za Zhi; 2014 Jul; 35(7):856-60. PubMed ID: 25294082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different inflammatory profile in young and elderly STEMI patients undergoing primary percutaneous coronary intervention (PPCI): Its influence on no-reflow and mortality.
    Del Turco S; Basta G; De Caterina AR; Sbrana S; Paradossi U; Taddei A; Trianni G; Ravani M; Palmieri C; Berti S; Mazzone A
    Int J Cardiol; 2019 Sep; 290():34-39. PubMed ID: 31079969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Somuncu MU; Akgun T; Cakır MO; Akgul F; Serbest NG; Karakurt H; Can M; Demir AR
    J Atheroscler Thromb; 2019 Nov; 26(11):970-978. PubMed ID: 30996145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Correlation of serum uric acid levels with coronary flow in patients with ST-segment elevation myocardial infarction undergoing primary coronary intervention].
    Wang JW; Chen YD; Wang CH; Zhu XL
    Zhonghua Yi Xue Za Zhi; 2012 Nov; 92(44):3100-3. PubMed ID: 23328417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endothelin-1 release in acute myocardial infarction as a predictor of long-term prognosis and no-reflow assessed by contrast-enhanced magnetic resonance imaging.
    Eitel I; Nowak M; Stehl C; Adams V; Fuernau G; Hildebrand L; Desch S; Schuler G; Thiele H
    Am Heart J; 2010 May; 159(5):882-90. PubMed ID: 20435200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Usefulness of the SYNTAX score to predict "no reflow" in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Magro M; Nauta ST; Simsek C; Boersma E; van der Heide E; Regar E; van Domburg RT; Zijlstra F; Serruys PW; van Geuns RJ
    Am J Cardiol; 2012 Mar; 109(5):601-6. PubMed ID: 22177003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma apelin-12 levels may predict in-hospital major adverse cardiac events in ST-elevation myocardial infarction and the relationship between apelin-12 and the neutrophil/lymphocyte ratio in patients undergoing primary coronary intervention.
    Topuz M; Oz F; Akkus O; Sen O; Topuz AN; Bulut A; Ozbicer S; Okar S; Koc M; Gur M
    Perfusion; 2017 Apr; 32(3):206-213. PubMed ID: 27770057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Usefulness of The C-Reactive Protein/Albumin Ratio for Predicting No-Reflow in ST-elevation myocardial infarction treated with primary percutaneous coronary intervention.
    Karabağ Y; Çağdaş M; Rencuzogullari I; Karakoyun S; Artaç İ; İliş D; Yesin M; Çağdaş ÖS; Altıntaş B; Burak C; Tanboğa HI
    Eur J Clin Invest; 2018 Jun; 48(6):e12928. PubMed ID: 29577260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Morphological predictors for no reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction caused by plaque rupture.
    Soeda T; Higuma T; Abe N; Yamada M; Yokoyama H; Shibutani S; Ong DS; Vergallo R; Minami Y; Lee H; Okumura K; Jang IK
    Eur Heart J Cardiovasc Imaging; 2017 Jan; 18(1):103-110. PubMed ID: 26800769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of no-reflow phenomena after primary percutaneous coronary intervention: a time-dependent analysis of mortality.
    Choo EH; Kim PJ; Chang K; Ahn Y; Jeon DS; Lee JM; Kim DB; Her SH; Park CS; Kim HY; Yoo KD; Jeong MH; Seung KB
    Coron Artery Dis; 2014 Aug; 25(5):392-8. PubMed ID: 24625688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The neutrophil to lymphocyte ratio was associated with impaired myocardial perfusion and long term adverse outcome in patients with ST-elevated myocardial infarction undergoing primary coronary intervention.
    Sen N; Afsar B; Ozcan F; Buyukkaya E; Isleyen A; Akcay AB; Yuzgecer H; Kurt M; Karakas MF; Basar N; Hajro E; Kanbay M
    Atherosclerosis; 2013 May; 228(1):203-10. PubMed ID: 23489347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The relationship between neutrophil/lymphocyte ratio and infarct-related artery patency before mechanical reperfusion in patients with ST-elevation myocardial infarction.
    Kurtul A; Murat SN; Yarlioglues M; Duran M; Karadeniz M; Ergun G; Ocek AH
    Coron Artery Dis; 2014 Mar; 25(2):159-66. PubMed ID: 24326783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of initial and residual thrombus burden on the no-reflow phenomenon in patients with ST-segment elevation myocardial infarction.
    Ahn SG; Choi HH; Lee JH; Lee JW; Youn YJ; Yoo SY; Cho BR; Lee SH; Yoon J
    Coron Artery Dis; 2015 May; 26(3):245-53. PubMed ID: 25503419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and validation of a clinical risk score predicting the no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Wang JW; Chen YD; Wang CH; Yang XC; Zhu XL; Zhou ZQ
    Cardiology; 2013; 124(3):153-60. PubMed ID: 23485798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma osteoprotegerin level on admission is associated with no-reflow phenomenon after primary angioplasty and subsequent left ventricular remodeling in patients with acute ST-segment elevation myocardial infarction.
    Erkol A; Oduncu V; Pala S; Kızılırmak F; Kılıcgedik A; Yılmaz F; Güler A; Karabay CY; Kırma C
    Atherosclerosis; 2012 Mar; 221(1):254-9. PubMed ID: 22265272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.